Nano-Ditech Corporation


Who We Are

About Us

Who We Are

Pioneer and Innovator for
in vitro Diagnostics

Founded in 2002, Nano-Ditech Corp specializes in the development and manufacture of high quality rapid immuno-diagnostic products to serve the point-of-care marketplace including medical professionals, physicians, clinical laboratories, and hospitals.

We focus on rapid POCT immunoassays for the detection of drugs of abuse, inflammation, and cardiac markers in the emergency department. Nano-Ditech’s key workforce has extensive experience in the IVD industry and utilizes their experience to satisfy customer needs by ensuring the highest level of product quality.

Nano-Ditech is proud to be among the few that have a track record for successfully developing test devices through the development of raw materials and obtaining US FDA and CE clearance. Nano-Ditech’s unique techniques have enabled us to rapidly develop all classes of monoclonal antibodies for each of the illicit drugs and cardiac disease markers to be specifically used for the rapid assay.

Nano-Ditech’s expert keep optimal quality control to provide a very high price/performance ratio of products. Nano-Ditech also has developed a new generation of immunoassay device called Europium based TRF (Time Resolved Florescence) immune assay. This single use diagnostic device will provide a new platform technology for the growing IVD market. The innovative technology will be further developed as a variety of POC diagnostic products through the collaboration of Nano-Ditech’s proprietary technologies or external partnering arrangements. In 2014, we successfully commercialized the technology with a unique TRF device reader and data management system. This diagnostic device system can be applied to various immunoassays used today requiring a highly sensitive and accurate standard.

Nano-Ditech has expanded its product offerings to include tests for COVID-19, sepsis, and other infectious diseases. The company is also developing new immunoassay technologies that will enable the development of even more accurate and sensitive POC diagnostic tests.